Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23941210 | 1.00 | ALOX5 (0.35) | ALOX5KDM4EALDH1A1HPGDFNTA | |
| SCHEMBL22863234 | 0.99 | ALOX5 (0.36) | ALOX5KDM4EALDH1A1HPGDFNTA | |
| SCHEMBL23941206 | 0.99 | ALOX5 (0.36) | ALOX5KDM4EALDH1A1HPGDFNTA | |
| SCHEMBL13746651 | 0.94 | APP (0.35) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL22863208 | 0.94 | ALOX5 (0.42) | ALOX5BACE1 | |
| SCHEMBL22863355 | 0.94 | ALOX5 (0.37) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL23941477 | 0.94 | ALOX5 (0.37) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL22863225 | 0.92 | KDM4E (0.33) | ALOX5KDM4EALDH1A1HPGDPTGER4 | |
| SCHEMBL9880206 | 0.90 | ALOX5 (0.44) | ALOX5NR1H4BACE1APPPTPN1 | |
| SCHEMBL9880205 | 0.90 | ALOX5 (0.44) | ALOX5NR1H4BACE1APPPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA UNIVERSITY (JP) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | ALOX5 71/4885KDM4E 2764/4885ALDH1A1 342/4885 |
| US-20210000794-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | ALOX5 117/4885KDM4E 3932/4885ALDH1A1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.